Fellin G, Graffer U, Bolner A, Ambrosini G, Caffo O, Luciani L
Department of Radiotherapy, Ospedale S. Chiara, Trento, Italy.
Br J Urol. 1997 Jul;80(1):44-9. doi: 10.1046/j.1464-410x.1997.00221.x.
To assess in a phase II trial the effectiveness and toxicity of combined chemotherapy and radiation with selective bladder preservation by response in the treatment of muscle-invasive bladder carcinoma.
Fifty-six eligible patients with T2-4 M0 transitional cell bladder cancer suitable for radical surgery and multi-agent chemotherapy received two courses of methotrexate, cisplatin and vinblastine, followed by 40 Gy of pelvic radiotherapy in 1.8 Gy fractions with concomitant cisplatin. Tumour response was evaluated by cystoscopy and biopsy. Those responding completely were given a 24 Gy bladder boost plus cisplatin; patients with residual tumour were assigned to immediate cystectomy.
After induction therapy, 28 patients (50%) responded completely; 22 operable patients with residual tumour underwent immediate cystectomy, while 34 patients were consolidated with cisplatin and radiation. Bladder relapses developed in 16 patients; seven had successful endovesical therapy for superficial disease and salvage cystectomy was possible in four of nine cases with invasive recurrence. Distant metastases occurred in 22 cases (39%). After a median follow-up of 46 months, the 5-year actuarial disease-specific survival was 59%, disease-free survival 54% and local control without cystectomy (bladder preservation) 41%. There were no treatment-related deaths; grade 3 late complications occurred in two patients.
This combined chemotherapy-radiotherapy regimen with selective organ preservation should be considered as an option for muscle-invasive bladder carcinoma. The initial results suggest the possibility of retaining a functioning bladder in many patients, without compromising survival, compared with elective cystectomy approaches. A longer follow-up and quality-of-life assessment remain essential for a better definition of selection criteria and long-term results of this combined modality.
在一项II期试验中,通过反应评估联合化疗和放疗并选择性保留膀胱治疗肌层浸润性膀胱癌的有效性和毒性。
56例符合条件的T2-4 M0期移行细胞膀胱癌患者,适合进行根治性手术和多药化疗,接受了两疗程的甲氨蝶呤、顺铂和长春碱治疗,随后进行盆腔放疗,剂量为40 Gy,每次1.8 Gy,同时给予顺铂。通过膀胱镜检查和活检评估肿瘤反应。完全缓解的患者接受24 Gy的膀胱追加放疗加顺铂;有残留肿瘤的患者接受即刻膀胱切除术。
诱导治疗后,28例患者(50%)完全缓解;22例有残留肿瘤的可手术患者接受了即刻膀胱切除术,而34例患者接受了顺铂和放疗巩固治疗。16例患者发生膀胱复发;7例浅表疾病患者成功接受了膀胱内治疗,9例浸润性复发患者中有4例可行挽救性膀胱切除术。22例(39%)发生远处转移。中位随访46个月后,5年精算疾病特异性生存率为59%,无病生存率为54%,未行膀胱切除术(保留膀胱)的局部控制率为41%。无治疗相关死亡;2例患者出现3级晚期并发症。
这种联合化疗放疗方案及选择性器官保留应被视为肌层浸润性膀胱癌患者的一种选择。初步结果表明,与选择性膀胱切除术相比,许多患者有可能保留功能正常的膀胱,且不影响生存率。更长时间的随访和生活质量评估对于更好地确定该联合治疗方式的选择标准和长期结果仍然至关重要。